GIACINTI, SILVANA
 Distribuzione geografica
Continente #
NA - Nord America 368
EU - Europa 105
AS - Asia 42
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 517
Nazione #
US - Stati Uniti d'America 356
IT - Italia 36
SE - Svezia 29
IE - Irlanda 19
IN - India 18
CN - Cina 13
CA - Canada 10
SG - Singapore 10
DE - Germania 5
BG - Bulgaria 4
FI - Finlandia 2
FR - Francia 2
GB - Regno Unito 2
MX - Messico 2
NL - Olanda 2
CH - Svizzera 1
EU - Europa 1
HU - Ungheria 1
IR - Iran 1
RO - Romania 1
TG - Togo 1
UA - Ucraina 1
Totale 517
Città #
Fairfield 53
Chandler 38
Ashburn 31
Woodbridge 29
Houston 25
Seattle 25
Wilmington 23
Cambridge 21
Dublin 19
Rome 19
Princeton 11
Ottawa 8
San Diego 7
San Paolo di Civitate 7
Beijing 6
Ann Arbor 5
Boston 5
Lawrence 5
Millbury 5
Plano 5
Sofia 4
Ladispoli 3
Patna 3
Dearborn 2
Köln 2
Toronto 2
Andover 1
Bremen 1
Columbus 1
Des Moines 1
Falkenstein 1
Glassboro 1
Hebei 1
Helsinki 1
Jinan 1
Kilburn 1
Leawood 1
Lomé 1
Montclair 1
Nanjing 1
Norwalk 1
Redmond 1
Redwood City 1
Senigallia 1
Shanghai 1
Singapore 1
Wandsworth 1
Zanjan 1
Totale 385
Nome #
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort 85
Castration resistance prostate cancer. what is in the pipeline? 59
null 57
null 52
null 51
null 48
A 17-gene expression signature for early identification of poor prognosis in clear cell renal cell carcinoma 41
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients. An Italian Analysis of Patients' Satisfaction 38
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. An Italian multicenter real life study 33
Enzalutamide in patients with castration-resistant prostate cancer. retrospective, multicenter, real life study 31
Molecular basis of drug resistance and insights for new treatment approaches in mCRPC 16
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression. real life experience from a multicenter cohort 13
Heterogeneity of PD-L1 expression and relationship with biology of NSCLC 10
Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy 10
Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma 9
Oligoprogression during Abiraterone therapy treated with radiotherapy in mCRPC patients. 8
Totale 561
Categoria #
all - tutte 1.782
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.782


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201940 0 0 0 0 0 0 0 0 0 0 23 17
2019/2020110 14 4 0 5 10 11 20 16 14 9 2 5
2020/202157 9 4 1 0 11 8 1 2 11 2 7 1
2021/2022110 11 4 8 10 10 5 0 13 4 6 18 21
2022/2023151 17 19 4 14 19 18 7 13 21 5 7 7
2023/202455 6 7 2 8 7 8 2 3 0 6 6 0
Totale 561